Company / Gross Margin
Serina Therapeutics, Inc. Gross Margin History
FY2018-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Margin
3.2%
FY2023
5-year range
3.2% / 86.8%
FY2019-FY2023
Trend
-94.8%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from 86.8% to 3.2% over the past 2 years.
Based on SEC 10-K filings.
3.2% in FY2023 with a 5-year CAGR of -70.7%.
Declined from 86.8% to 3.2% over the past 2 years.
Gross Margin over time
Growth rates
- 3-Year Change
- -82.6pp
- 5-Year Change
- -70.7pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2023, gross margin decreased 94.8% year-over-year.
- Peak gross margin was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -18.20 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | 3.2% | -94.8% |
| FY2022 | 61.8% | -28.9% |
| FY2021 | 86.8% | +1.1% |
| FY2020 | 85.9% | +16.2% |
| FY2018 | 73.9% | - |
As of FY2023 · SEC 10-K Annual Filings · Updated Jun 24, 2026